A. Schematic representation of a conventional human Ig, camelid HCab, and a nanobody. B. Schematic overview of the tumor-associated targets for which nanobodies have currently been established. Important targets are immune cell markers, tumor cell (membrane) proteins, receptor ligands, and proteins associated with the tumor microenvironment.